| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/04/2012 | EP1907582B1 Ect2 as a therapeutic target for esophageal cancer |
| 01/04/2012 | EP1827101B1 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 01/04/2012 | EP0914142B9 Peptides with increased binding affinity for at least three hla-a3-like molecules |
| 01/04/2012 | CN102307593A Modulation of axon degeneration |
| 01/04/2012 | CN102304570A Compositions and methods for cancer diagnosis and therapy |
| 01/04/2012 | CN102304538A Construction and screening as well as applications for siRNAs expression carrier of stomach cancer target STAT3 gene |
| 01/04/2012 | CN102304527A Enterococcus antigens |
| 01/04/2012 | CN102304515A RNA interference sequence aiming at hepatocyte nuclear factor 4a and applications thereof |
| 01/04/2012 | CN102302788A Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 01/04/2012 | CN101831461B Human small RNA-148a expression vector and use thereof |
| 01/04/2012 | CN101643731B DDK-1 specific siRNA and application thereof in treatment of rheumatoid arthritis |
| 01/04/2012 | CN101272798B Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer |
| 01/03/2012 | US8090542 Functional and hyperfunctional siRNA |
| 01/03/2012 | US8088914 MicroRNA and methods for inhibiting same |
| 01/03/2012 | US8088913 Compositions and methods for therapy and diagnosis of cancer |
| 01/03/2012 | US8088902 Isolated nucleic acid molecule comprising the sequence of a DNA virus microRNA; Epstein barr virus; inhibiting microRNP activity in a cell |
| 01/03/2012 | US8088893 Hypoxia inducing factors and uses thereof for inducing angiogenesis and improving muscular functions |
| 01/03/2012 | US8088752 Methods for metabolic modulation |
| 01/03/2012 | US8088751 Pharmaceutical composition for treating dementia comprising ShRNA inhibiting S100a9 expression |
| 01/03/2012 | US8088749 Compositions and methods for treating cancer |
| 01/03/2012 | US8088622 P27 and P21 in gene therapies |
| 01/03/2012 | US8088568 Dermal micro-organs, methods and apparatuses for producing and using the same |
| 01/03/2012 | US8088390 Methods for the early diagnosis of ovarian cancer |
| 01/03/2012 | US8088388 Complexing; water in oil emulsion; immunostimulant |
| 01/03/2012 | US8088361 Treatment of allergic rhinitis in mammals with Clostridia neurotoxins |
| 01/03/2012 | US8088360 Treatment of infectious rhinitis in mammals with clostridia neurotoxins |
| 01/03/2012 | CA2514873C Compositions and methods for inhibiting tumor growth and metastasis |
| 01/03/2012 | CA2501744C Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| 01/03/2012 | CA2501708C Mammalian artificial chromosome |
| 01/03/2012 | CA2475604C An herpes simplex virus complex |
| 01/03/2012 | CA2420618C Percarboxylated polysaccharides, and a process for their preparation |
| 01/03/2012 | CA2419954C Use of il-6r/il-6 chimera in huntington's disease |
| 01/03/2012 | CA2388180C Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule |
| 01/03/2012 | CA2379539C Feline calicivirus genes and vaccines, in particular recombinant vaccines |
| 01/03/2012 | CA2347025C Zinc finger binding domains for gnn |
| 01/03/2012 | CA2334960C Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases |
| 01/03/2012 | CA2282719C A method for producing procollagen |
| 01/03/2012 | CA2261346C Polynucleotide vaccine formula for treating porcine respiratory and reproductive diseases |
| 01/03/2012 | CA2260855C Polynucleotide vaccine formula in particular against bovine respiratory pathology |
| 01/03/2012 | CA2229811C Inverted chimeric and hybrid oligonucleotides |
| 01/03/2012 | CA2226973C Modulators of the function of fas receptors and other proteins |
| 01/03/2012 | CA2224468C P53 protein variants and therapeutical uses thereof |
| 01/03/2012 | CA2210998C Inhibition of neovascularization using vegf-specific oligonucleotides |
| 01/03/2012 | CA2209771C Combined therapeutical treatment of hyperproliferative diseases |
| 12/29/2011 | WO2011163554A2 Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis |
| 12/29/2011 | WO2011163512A2 Cancer therapy |
| 12/29/2011 | WO2011163499A2 Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| 12/29/2011 | WO2011162419A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 12/29/2011 | WO2011162115A1 PHARMACEUTICAL COMPOSITION UTILIZING PANCREATIC β CELL PROLIFERATION FACTOR |
| 12/29/2011 | WO2011160860A1 Compositions for antiseptic processing of woven materials |
| 12/29/2011 | WO2011160563A1 Novel porcine interferon and use thereof |
| 12/29/2011 | WO2011097027A3 Methods for treating or inhibiting infection by clostridium difficile |
| 12/29/2011 | WO2011091390A3 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| 12/29/2011 | WO2011085347A3 Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
| 12/29/2011 | WO2011072247A3 Pathogen restriction factors |
| 12/29/2011 | WO2002031116A9 Gene expression modulated in spontaneous inflammatory bowel disease |
| 12/29/2011 | US20110319493 Histone deacetylases, and uses related thereto |
| 12/29/2011 | US20110319480 Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens |
| 12/29/2011 | US20110319479 Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| 12/29/2011 | US20110319474 siRNA targeting cyclin-dependent kinase 4 (CDK4) |
| 12/29/2011 | US20110319469 SNPs of Apolipoprotein B and Modulation of Their Expression |
| 12/29/2011 | US20110318834 Multiple-tumor aberrant growth genes |
| 12/29/2011 | US20110318833 Adipose-derived stem cells and laticces |
| 12/29/2011 | US20110318832 Human Telomerase Catalytic Subunit |
| 12/29/2011 | US20110318362 Novel card proteins involved in cell death regulation |
| 12/29/2011 | US20110318355 Mutant proteins of the f protein of piv-5 and piv-2 |
| 12/29/2011 | US20110318325 Inositol Pyrophosphates Determine Exocytotic Capacity |
| 12/29/2011 | US20110318318 Anti-apoptotic fusion proteins |
| 12/29/2011 | US20110318308 Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis |
| 12/29/2011 | CA2803913A1 Tumor growth controlling method targeting galactosylceramide expression factor-1 |
| 12/29/2011 | CA2803882A1 Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
| 12/28/2011 | EP2400021A2 ErbB3 based methods and compositions for treating neoplasms |
| 12/28/2011 | EP2400019A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400018A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400017A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400016A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400015A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400014A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400013A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400012A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400011A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400010A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400009A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400008A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400007A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400006A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400005A2 In tumours differentially expressed gene products and use of the same |
| 12/28/2011 | EP2400004A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2400003A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2400002A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2400001A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2400000A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399999A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399998A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399997A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399996A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399995A2 In tumours differentially expressed gene products and use of the same. |
| 12/28/2011 | EP2399948A1 Cationic poly(amino acids) and uses thereof |
| 12/28/2011 | EP2399924A2 Nuclease resistant double-stranded ribonucleic acid |
| 12/28/2011 | EP2399611A2 Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metasatases in cancer treatment |